España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
bluebird bio
BLUE
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$8.14
-0.21
-2.51%
At close: -
$8.32
0.18
2.20%
After Hours: 7:54 PM EDT
Get Report
Comment
bluebird bio (BLUE) Forecast
News
Earnings
bluebird bio (BLUE) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for bluebird bio (NASDAQ:BLUE) Stock
bluebird bio Stock (NASDAQ: BLUE)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, December 13, 2024
Trading Halt: Halted at 7:50:00 p.m. ET - Tra...
Benzinga Newsdesk
Monday, December 09, 2024
Reported Sunday, bluebird bio Highlights 9-Ye...
Benzinga Newsdesk
Saturday, December 07, 2024
bluebird bio Announced Long-Term Follow-Up Da...
Benzinga Newsdesk
Thursday, December 05, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
Wednesday, December 04, 2024
bluebird bio Announces 1-for-20 Reverse Stock...
Benzinga Newsdesk
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
Vandana Singh
Bluebird Bio shares are trading higher after ...
Benzinga Newsdesk
bluebird bio Joins CMMI Cell And Gene Therapy...
Benzinga Newsdesk
Friday, November 29, 2024
FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy
Vandana Singh
Wednesday, November 27, 2024
bluebird bio shares are trading lower after t...
Benzinga Newsdesk
FDA Investigating Serious Risk Of Hematologic...
Benzinga Newsdesk
Friday, November 15, 2024
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
Vandana Singh
RBC Capital Reiterates Sector Perform on blue...
Benzinga Newsdesk
B of A Securities Downgrades bluebird bio to ...
Benzinga Newsdesk
Barclays Maintains Overweight on bluebird bio...
Benzinga Newsdesk
Thursday, November 14, 2024
bluebird bio Sees Q4 2024 Revenue At Least $2...
Benzinga Newsdesk
bluebird bio Q3 2024 Adj EPS $(0.31) Beats $(...
Benzinga Newsdesk
Earnings Scheduled For November 14, 2024
Benzinga Insights
Wednesday, November 13, 2024
Exploring bluebird bio's Earnings Expectations
Benzinga Insights
Tuesday, November 05, 2024
bluebird bio To Present Additional Long-Term ...
Benzinga Newsdesk
Friday, October 11, 2024
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
Vandana Singh
Wednesday, September 25, 2024
The Analyst Verdict: bluebird bio In The Eyes Of 5 Experts
Benzinga Insights
Wells Fargo Maintains Equal-Weight on bluebir...
Benzinga Newsdesk
Tuesday, September 24, 2024
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year
Vandana Singh
Bluebird Bio Is Implementing A Restructuring ...
Benzinga Newsdesk
Monday, September 23, 2024
Bluebird Bio shares are trading higher after ...
Benzinga Newsdesk
Bluebird Bio Says Co And Henogen Sr Entered I...
Benzinga Newsdesk
Monday, September 16, 2024
Cantor Fitzgerald Reiterates Neutral on blueb...
Benzinga Newsdesk
Friday, August 23, 2024
bluebird bio Recieves Receipt Of Delinquency ...
Benzinga Newsdesk
Thursday, August 15, 2024
What 4 Analyst Ratings Have To Say About bluebird bio
Benzinga Insights
bluebird bio shares are trading lower after J...
Benzinga Newsdesk
B of A Securities Maintains Buy on bluebird b...
Benzinga Newsdesk
RBC Capital Reiterates Sector Perform on blue...
Benzinga Newsdesk
Barclays Maintains Overweight on bluebird bio...
Benzinga Newsdesk
This Snowflake Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Avi Kapoor
Baird Maintains Outperform on bluebird bio, L...
Benzinga Newsdesk
JP Morgan Downgrades bluebird bio to Neutral
Benzinga Newsdesk
Wednesday, August 14, 2024
bluebird bio shares are trading lower. The co...
Benzinga Newsdesk
bluebird bio Q2 Sales $16.100M Beat $10.661M ...
Benzinga Newsdesk
Monday, August 12, 2024
Y-mAbs Therapeutics, Inc. Reports Q2 Loss, Misses Revenue Estimates
Zacks
Wednesday, May 29, 2024
bluebird bio Says Continuing To Work Expediti...
Benzinga Newsdesk
bluebird bio Names James Sterling As CFO, Eff...
Benzinga Newsdesk
Thursday, May 09, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
Bluebird Bio shares are trading higher. The c...
Benzinga Newsdesk
bluebird bio Q1 Sales $18.600M Miss $19.551M ...
Benzinga Newsdesk
Friday, April 26, 2024
Bluebird Bio Announces Receipt Of Expected No...
Benzinga Newsdesk
Tuesday, April 16, 2024
Bluebird Bio Inc Anticipates It Will Be Delay...
Benzinga Newsdesk
Monday, April 15, 2024
Watching Bluebird Bio; Shares Spike Higher As...
Benzinga Newsdesk
Wednesday, March 27, 2024
Peeling Back The Layers: Exploring bluebird bio Through Analyst Insights
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch